New Studies Examine Potential Genetic Markers For Diabetes
- Volume 17 - Issue 6 - June 2004
- 5259 reads
- 0 comments
Two new international studies reveal intriguing findings in the realm of diabetes research. In the Finland-United States Investigation of NIDDM Genetics (FUSION) study, which involved over 1,200 patients, researchers identified 10 single nucleotide polymorphisms (SNPs) that are associated with type 2 diabetes in the Finnish population. According to the study, which was published in a recent issue of Diabetes, these SNPs were located within or close to the hepatocyte nuclear factor 4 alpha (HNF4A) gene, which influences the expression of glucose metabolic genes.
In a separate study, which was also published in the same issue of Diabetes, researchers focused on 600 Ashkenazi Jewish patients. Two hundred seventy-five of these patients had type 2 diabetes. These researchers also “found diabetes-related associations for SNPs in the same region of the HNF4A gene,” according to an article on www.ThatFootSite.com.
Gerit Mulder, DPM, cautions against reading too much into the studies as they do not clearly establish “a direct correlation” between genetic markers and the clinical progression of diabetes. However, he praises research efforts that recognize the importance of genetic predisposition for diseases such as diabetes.
“Determining a genetic marker that leads to the subsequent expression and development of a disease may significantly contribute to disease prevention through gene therapy or related treatment,” says Dr. Mulder, Director of the Wound Treatment and Research Center at the University of California-San Diego. “Preventing a disease through genetic manipulation could lead to a significant reduction in the prevalence of diabetes and its associated problems.”
Identifying patients who may be genetically predisposed to developing type 2 diabetes can go a long way toward more targeted patient education on reducing risk factors and making appropriate lifestyle changes, points out Dr. Mulder, who is an Associate Professor of Surgery and Orthopedics at the University of California-San Diego. He says that this can also help facilitate prevention of sequelae related to a disease such as diabetes.
Dr. Mulder adds that continued research in the area of genetic mapping may eventually have even more significant benefits in the future.
“As our knowledge of genetic mapping and marker identification increases, I anticipate reaching a point in medical care where the genome is manipulated or altered to reduce or eliminate select diseases,” says Dr. Mulder.
Is Antibiotic Approval On The Wane?
By Brian McCurdy, Associate Editor
Given the increasing prevalence of antibiotic-resistant infections such as methicillin-resistant Staph aureus (MRSA), there appears to be a need for new antibiotics. However, are drug companies meeting the need?
While there are 506 new drugs currently in the pipeline for approval, just six are antibiotics, according to a recent study in Clinical Infectious Diseases. Specifically, the study notes FDA approval of new antibacterial agents decreased by 56 percent in the last 20 years.
Both Benjamin Lipsky, MD, and David G. Armstrong, DPM, suggest that among the major causes of the decrease in approval for antibiotics are economic reasons, saying drug companies would have higher profits for drugs prescribed over a long period of time than for antibiotics taken for several days.
“If it costs a few hundred million dollars to bring a drug to market in 2004, then the drug company will want to put that toward an agent that is used for the life of the patient, not just for seven to 10 days,” says Dr. Armstrong, Professor of Surgery, Chair of Research and Assistant Dean at Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine.
Authors of the study emphasize that there is a critical need for new antimicrobial agents, citing the resistance of common pathogens to antibiotics, emerging new infections and the potential use of multidrug-resistant agents as bioweapons.
Dr. Lipsky, a Professor of Medicine at the University of Washington School of Medicine, notes that 10 years ago, many clinicians, researchers and pharmaceutical companies believed that all the antibiotics needed were available and “we’re now paying the price” as few drugs are under development.